Unlock instant, AI-driven research and patent intelligence for your innovation.

Chromogranin a as a marker for bladder cancer

A technology of chromogranin and bladder cancer, applied in the field of clinical diagnosis, can solve the problems of not evaluating the preoperative prognosis and follow-up value

Pending Publication Date: 2018-11-09
CEZANNE
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Bertaccini et al found a 10-fold decrease in serum CgA levels 1 month after cystoprostatectomy for Small Cell Urothelial Carcinoma (SCUC) compared to preoperative levels, but did not evaluate preoperative prognosis and follow-up values (Bertaccini et al. 2008)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chromogranin a as a marker for bladder cancer
  • Chromogranin a as a marker for bladder cancer
  • Chromogranin a as a marker for bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0041] The present invention relates to chromogranin A (CgA) as a marker for bladder cancer, especially non-neuroendocrine bladder cancer, and preferably urothelial cancer ) use of prognostic markers. Therefore, CgA can be used as a marker in in vitro assays for prognosis, risk assessment, risk stratification, monitoring and / or treatment control of bladder cancer, especially non-neuroendocrine bladder cancer, preferably urothelial cancer. In other words, CgA has been shown to be a good biomarker for assessing disease severity in bladder cancer patients, especially in non-neuroendocrine bladder cancer patients, preferably in urothelial cancer patients. Therefore, CgA can also be used in the management of patients with bladder cancer, especially non-neuroendocrine bladder cancer, preferably urothelial cancer ("patient management").

[0042] The present invention relates to a method for the prognosis of a subject with bladder cancer, in particular a subject with non-neuroendocri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of Chromogranin A (CgA) as a marker (particularly a prognostic marker) for bladder cancer, particularly non-neuroendocrine bladder cancer and preferably urothelial carcinoma. In particular, CgA can be used as a marker in an in vitro assay for the prognosis, risk assessment, risk stratification, monitoring and / or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma). The invention further pertains to a method for the prognosis, risk assessment, risk stratification, monitoring and / or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma) in a subject, comprising the step of determining the level of CgA and optionally MMP7 in a sample of a bodily fluid of said subject.

Description

technical field [0001] The invention belongs to the field of clinical diagnosis. In particular, the present invention relates to the prognosis, risk assessment, risk stratification, monitoring and / or treatment control of bladder cancer based on chromogranin A (CgA) as a marker. Background technique [0002] Bladder cancer (urinary bladder cancer) is the most common malignant tumor of the urinary tract. Considering newly diagnosed cases and its high recurrence rate, bladder cancer is one of the most prevalent cancers in the world (Chamie et al. 2011, Goodison, Rosser, and Urquidi 2013). Western countries are more affected, and men are 3 to 4 times more at risk of developing it compared to women (Burger et al. 2013a). [0003] Different types of bladder cancer can be distinguished based on the cells that become cancerous. The most common type of bladder cancer is transitional cell carcinoma (90%), followed by squamous cell carcinoma and adenocarcinoma (2 to 5%). Less than ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57407A61N5/00G01N33/57488
Inventor 贝内迪克特·雅尔丹-瓦特莱尼古拉斯·布古安蒂博尔·绍尔沃什
Owner CEZANNE